Articles

Compelling efficacy data for sacituzumab govitecan-hziy results in FDA fast-track approval for its use in metastatic triple-negative breast cancer. Read More ›

Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence. Read More ›

Sacituzumab govitecan-hziy, for the second-line treatment of patients with metastatic triple-negative breast cancer, is a cytotoxic drug that has specific storage, reconstitution, and administration instructions for adherence. Read More ›

The optimal risk-to-benefit dosage of sacituzumab govitecan-hziy is 10 mg/kg, calculated from dose-escalation and dose-expansion studies. Read More ›

Antibody–drug conjugates are at the leading edge of innovation and efficacy in breast cancer treatment. Research efforts continue in order to establish further novel targets and thus further advance patient outcomes. Read More ›

Rush University Cancer Center in Chicago, IL, is well known for providing patients with outstanding cancer care, including immunotherapies, targeted therapies, and minimally invasive surgical options. Read More ›

The ongoing COVID-19 pandemic has brought to the forefront the importance of advance care planning. Read More ›